Syngene

Syngene company information, Employees & Contact Information

Explore related pages

Related company profiles:

Syngene provides instruments, software and systems for documenting and analysing gels used by molecular biologists in genomic and proteomic studies. Almost all research in the biological sciences involves understanding the underlying molecular processes involving DNA, RNA and proteins, and gel electrophoresis is a fundamental process in many laboratories working in this area. Syngene are industry experts, providing optical imaging to suit your needs. Syngene products range from low-cost entry-level kits to fully computer-controlled automatic analysers for fluorescence, chemiluminescence and proteomics workstations. • Gel documentation (gel doc) and image analysis systems for DNA and protein gels. • Chemiluminescence and fluorescence systems for Western blots and probes. • Proteomics hardware and software for 2D gel electrophoresis (2DGE). We are headquartered in Cambridge, a thriving scientific hub in the UK and have a centrally located US subsidiary in Frederick, USA. Globally, our products are supported by an international network of highly-trained distributors, all of whom employ imaging specialists.

Company Details

Employees
56
Founded
-
Address
Beacon House, Nuffield Road,united Kingdom
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, Cambs
Looking for a particular Syngene employee's phone or email?

Syngene Questions

News

Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development - PR Newswire UK

Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development PR Newswire UK

Syngene Acquires its First Manufacturing Facility in the US - PR Newswire

Syngene Acquires its First Manufacturing Facility in the US PR Newswire

Syngene Wins Awards for Innovation, Business Expansion, and Environmental Excellence - Pharmaceutical Technology

Syngene Wins Awards for Innovation, Business Expansion, and Environmental Excellence Pharmaceutical Technology

Orocidin and Syngene Partner to Accelerate Biotech Innovation - Yahoo Finance

Orocidin and Syngene Partner to Accelerate Biotech Innovation Yahoo Finance

India's Syngene International acquires first US biologics facility for $36.5 mln - Reuters

India's Syngene International acquires first US biologics facility for $36.5 mln Reuters

Indian contractor Syngene throws down $37M for Emergent's Baltimore biologics plant - Fierce Pharma

Indian contractor Syngene throws down $37M for Emergent's Baltimore biologics plant Fierce Pharma

Syngene International invests in dedicated peptide laboratory and advanced automation - PR Newswire UK

Syngene International invests in dedicated peptide laboratory and advanced automation PR Newswire UK

Syngene International announces third year of STEM scholarship and mentorship program for women in collaboration with RICH - Press Trust of India

Syngene International announces third year of STEM scholarship and mentorship program for women in collaboration with RICH Press Trust of India

Syngene CEO Jonathan Hunt Steps Down, Peter Bains Appointed - Business News - Rediff MoneyWiz

Syngene CEO Jonathan Hunt Steps Down, Peter Bains Appointed - Business News Rediff MoneyWiz

Syngene International Limited announces Q1FY26 financial results for the quarter ended 30th June 2025 - Global Prime News

Syngene International Limited announces Q1FY26 financial results for the quarter ended 30th June 2025 Global Prime News

Syngene's MD & CEO Jonathan Hunt steps down, Peter Bains named as new CEO - The Economic Times

Syngene's MD & CEO Jonathan Hunt steps down, Peter Bains named as new CEO The Economic Times

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% Biocon

Priyadarshini Mahapatra to exit Syngene International as Head Legal, Company Secretary & Compliance... - Medical Dialogues

Priyadarshini Mahapatra to exit Syngene International as Head Legal, Company Secretary & Compliance... Medical Dialogues

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr - Biocon

Biocon Q3FY25 Revenue at Rs 3,856 Cr, Up 7%# EBITDA at Rs 787 Cr, Up 16%#; Net Profit at Rs 25 Cr Biocon

Syngene International appoints Sanjay Nandavadekar as Associate VP (IT) - ET CIO

Syngene International appoints Sanjay Nandavadekar as Associate VP (IT) ET CIO

Pharmaceutical Technology Excellence Awards 2022: Syngene International - Pharmaceutical Technology

Pharmaceutical Technology Excellence Awards 2022: Syngene International Pharmaceutical Technology

Syngene and Zumutor partner to screen antibody libraries for new drugs - Fierce Biotech

Syngene and Zumutor partner to screen antibody libraries for new drugs Fierce Biotech

Syngene International announces the winners of the 2nd edition of the Annual Science Quiz held in Dakshin Kannada, Bangalore and Hyderabad - PR Newswire

Syngene International announces the winners of the 2nd edition of the Annual Science Quiz held in Dakshin Kannada, Bangalore and Hyderabad PR Newswire

Biocon Q2FY25 Revenue at Rs 3,623 Cr, EBITDA at Rs 718 Cr - Biocon

Biocon Q2FY25 Revenue at Rs 3,623 Cr, EBITDA at Rs 718 Cr Biocon

Are Syngene International Limited's (NSE:SYNGENE) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - simplywall.st

Are Syngene International Limited's (NSE:SYNGENE) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? simplywall.st

Biocon's Syngene to build a plant in India - Fierce Pharma

Biocon's Syngene to build a plant in India Fierce Pharma

Syngene's playbook: 50% revenue from contract manufacturing in 2-3 years - Business Standard

Syngene's playbook: 50% revenue from contract manufacturing in 2-3 years Business Standard

Syngene International Promoter Sells 2% Stake for Rs 686 Crore - Rediff MoneyWiz

Syngene International Promoter Sells 2% Stake for Rs 686 Crore Rediff MoneyWiz

SYNGENE Share Price Today - Syngene International on NSE/BSE - scanx.trade

SYNGENE Share Price Today - Syngene International on NSE/BSE scanx.trade

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus - Nature

Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus Nature

New GENi System Extends Syngene’s Gel Documentation Range - European Pharmaceutical Review

New GENi System Extends Syngene’s Gel Documentation Range European Pharmaceutical Review

New stain-free gel visualisation application of syngene’s G:BOX system - Scientist Live

New stain-free gel visualisation application of syngene’s G:BOX system Scientist Live

Syngene’s winning formula - Fortune India

Syngene’s winning formula Fortune India

Syngene plans to invest ₹788 cr. to expand operations in Hyderabad’s Genome Valley - The Hindu

Syngene plans to invest ₹788 cr. to expand operations in Hyderabad’s Genome Valley The Hindu

Syngene to launch upgraded biologics facility in Bangalore, India - ALCHEMPro

Syngene to launch upgraded biologics facility in Bangalore, India ALCHEMPro

Syngene International Q2 results: PAT down by 8.93%, revenue drops by 2% - Business Standard

Syngene International Q2 results: PAT down by 8.93%, revenue drops by 2% Business Standard

G:BOX EF Imaging System used at Major Plant Breeding Centre - European Pharmaceutical Review

G:BOX EF Imaging System used at Major Plant Breeding Centre European Pharmaceutical Review

Syngene Reports ₹1,018 Crore Revenue in Q4 FY25 - India Infoline

Syngene Reports ₹1,018 Crore Revenue in Q4 FY25 India Infoline

SYNGENE Stock Price and Chart — NSE:SYNGENE - TradingView

SYNGENE Stock Price and Chart — NSE:SYNGENE TradingView

Biocon confirms sale of 80 lakh Syngene Intl shares for ₹686 crore via open market block deal - CNBC TV18

Biocon confirms sale of 80 lakh Syngene Intl shares for ₹686 crore via open market block deal CNBC TV18

Syngene International shares plummet 13%: Here’s what’s worrying investors - financialexpress.com

Syngene International shares plummet 13%: Here’s what’s worrying investors financialexpress.com

Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi - Biocon

Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi Biocon

Syngene Named One Of The ‘World’s Most Sustainable Companies 2025’ by TIME Magazine & Statista - Passionate In Marketing

Syngene Named One Of The ‘World’s Most Sustainable Companies 2025’ by TIME Magazine & Statista Passionate In Marketing

Analysis of Syngene International share Price - getmoneyrich

Analysis of Syngene International share Price getmoneyrich

Top Syngene Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant